TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27259583
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS) application via soak and smear (SS)
Study: 27259583
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS) application to dry skin
Study: 7747682
Drug: d-sotalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol (200 mg/day)
Study: 2117891
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of recombinant interferon-beta (IFN-beta) at 6 x 10(6) units continuously for 14 days from the day of operation.
Study: 12478216
Drug: Alcohol (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.80 g/kg)
Study: 28567578
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, two boluses at 3 and 6 hours later (group A)
Study: 28567578
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, one bolus at 9 hours later (group B)
Study: 26458939
Drug: Dalbavancin 500
Normalized name: dalbavancin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin 500 mg
Study: 23433688
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of DHA
Study: 23433688
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil capsules
Study: 21243486
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nasal nicotine
Study: 11673582
Drug: Low-dose vigabatrin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vigabatrin (18-36 mg/kg/day)
Study: 11673582
Drug: High-dose vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vigabatrin (100-148 mg/kg/day)
Study: 11673582
Drug: High-dose vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vigabatrin
Study: 11673582
Drug: Vigabatrin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (both doses)
Study: 9502190
Drug: euglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: euglycaemic clamp [glucose 5 mmol L(‐1)]
Study: 9502190
Drug: hyperglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperglycaemic clamp [glucose 15 mmol L(‐1)]
Study: 9502190
Drug: euglycaemic hyperinsulinaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: euglycaemic hyperinsulinaemic clamp [glucose 5 mmol L(‐l)]
Study: 9502190
Drug: intrajejunal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrajejunal infusion of lipid (Lipofundin medium‐chained triglyceride 10%)
Study: 24604685
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) combined with methylprednisolone (MPred) - EPO dosage: 20,000 U/24 h, MPred dosage: 1,000 mg/24 h for five consecutive days.
Study: 24604685
Drug: Methylprednisolone (MPred)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MPred) alone - MPred dosage: 1,000 mg/24 h for five consecutive days, placebo for EPO.
Study: 20410083
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (10 mg iron, 375 microg vitamin A, 4.2 mg zinc, 225 microg folic acid, 1.35 microg vitamin B-12 per child per day)
Study: 16040923
Drug: iohexol [300
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol [300 mg of iodine per milliliter]
Study: 16040923
Drug: iodixanol [320
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol [320 mg I/mL]
Study: 16040923
Drug: iomeprol [350
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol [350 mg I/mL]
Study: 16040923
Drug: iomeprol [400
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol [400 mg I/mL]
Study: 3189898
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.3 mg
Study: 10230955
Drug: Phentolamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (0.2 mg/kg) during cooling and rewarming periods of CPB
Study: 6824358
Drug: Potent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent and midstrength topical steroids
Study: 6824358
Drug: Simple lubricating
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple lubricating agents
Study: 6824358
Drug: Irradiated five
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated five times weekly
Study: 6824358
Drug: Irradiated three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated three times weekly
Study: 3902420
Drug: Aspartame (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (2.7 g per day for 18 weeks)
Study: 3902420
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical appearing capsules)
Study: 30120406
Drug: Capsule vitamin
Normalized name: vitamin A Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule vitamin D (CG)
Study: 22878647
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1,000 mg/day) and E (400 I.U./day) supplementation for 1 year
Study: 22878647
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cholinergic medication only)
Study: 9033826
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Propofol then an epidural lumbar block with bupivacaine 0.25% (single shot) and continuous propofol i.v. infusion
Study: 6394515
Drug: Cotrimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day for 7 days)
Study: 6394515
Drug: Cefadroxil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (500 mg twice a day for 7 days)
Study: 30784788
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release group (n=18) receiving four sessions of myofascial treatment, each lasting 40 minutes.
Study: 21994966
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment in PAI women
Study: 10593367
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (90 mg) once daily
Study: 1711274
Drug: H1- +
Normalized name: Histamine H1 Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1- + H2- antagonists
Study: 6363098
Drug: Terbutaline 1
Normalized name: terbutaline 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1 mg from a pressurised aerosol
Study: 6363098
Drug: Terbutaline 1
Normalized name: terbutaline 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1 mg from a nebuliser
Study: 6363098
Drug: Terbutaline 1
Normalized name: terbutaline 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1 mg from a pressurised aerosol with a pear‐shaped, 750 ml spacer
Study: 6363098
Drug: Terbutaline 1
Normalized name: terbutaline 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1 mg from a nebuliser with Intermittent Positive Pressure Ventilation (I.P.P.V.)
Study: 6363098
Drug: Terbutaline 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 4 mg from a nebuliser
Study: 22958623
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (increasing doses to achieve target resting HR <70 beats per minute)
Study: 22958623
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (increasing doses)
Study: 16702899
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response (IVR) administered Hamilton Depression Rating Scale (HAM-D) scores before randomization
Study: 12806565
Drug: 12-g piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-g piracetam infusion
Study: 26876349
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement (n = 20)
Study: 26876349
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement (n = 20)
Study: 22377805
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (valgus knee brace, customised neutral foot orthoses, shoes designed for motion control)
Study: 22377805
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (neutral knee brace, flat unsupportive foot orthoses, shoes with flexible mid‐sole)
Study: 16318658
Drug: 2.3 mL
Normalized name: Evkeeza 345 MG in 2.3 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 mL of 0.5% levobupivacaine with fentanyl 15 microg
Study: 16318658
Drug: 2.6 mL
Normalized name: gemcitabine 2 GM in 52.6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 mL of 0.5% levobupivacaine alone
Study: 10797115
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (CHO) - 250 ml of an 8% carbohydrate‐electrolyte solution every 15 min
Study: 3496470
Drug: Three-day antibiotic
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day antibiotic treatment
Study: 3496470
Drug: Suppressive antibiotics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive antibiotics, treatment of asymptomatic urinary tract infections, full course antibiotic therapy
Study: 3496470
Drug: Placebo, treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, treatment of symptomatic urinary tract infection only, short course therapy
Study: 25264990
Drug: Latanoprost/Timolol Fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost/Timolol Fixed Combination (LTFC)
Study: 25264990
Drug: Latanoprost and
Normalized name: latanoprost and netarsudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost and Timolol Gel-forming Solution Unfixed Combination (LTuFC)
Study: 21319355
Drug: 0.25 μg.kg⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 μg.kg⁻¹ remifentanil
Study: 17046300
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg montelukast (M)
Study: 29275582
Drug: Lansoprazole Capsules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole Capsules + Mosapride Citrate + Shuganjieyu capsule
Study: 29275582
Drug: Lansoprazole Capsules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole Capsules + Mosapride Citrate + Deanxit + Shuganjieyu capsule
Study: 29275582
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Lansoprazole Capsules + Mosapride Citrate)
Study: 18374753
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vascular endothelial growth factor (VEGF) and L‐arginine (6 g per day for 3 months)
Study: 2124732
Drug: Diazepam enema
Normalized name: diazepam Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam enema (0.5 mg/kg bodyweight) in lateral position
Study: 6101337
Drug: H1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 plus H2 blocker (hydroxyzine HCl + cimetidine)
Study: 7402688
Drug: H2 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blocker (cimetidine)
Study: 28256066
Drug: nab-paclitaxel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (150 mg/m2 once per week for 3 of 4 weeks)
Study: 22209190
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 or 30 mg/day
Study: 22209190
Drug: Lithium 900,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 900, 1200 or 1500 mg/day
Study: 19160399
Drug: Concurrent ESS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent ESS and CR
Study: 10716064
Drug: Tiludronate 400
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 400 mg
Study: 28087723
Drug: Prophylactic propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic propranolol (0.5 mg/kg/dose every 12 hours)
Study: 27518319
Drug: Itopride 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 100 mg t.d.s.
Study: 12430877
Drug: Total Therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Therapy II (TT II) with thalidomide at a starting dose of 400 mg
Study: 7039666
Drug: Oral timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral timolol (5 mg to 30 mg per day)
Study: 7039666
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol and adrenaline
Study: 26408273
Drug: sulodexide 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulodexide 500 lipasemic units twice daily
Study: 20924753
Drug: TFMPP (0.94
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFMPP (0.94 mg/kg, oral)
Study: 19763062
Drug: Rub-and-spray method
Normalized name: betamethasone / gentamicin Topical Spray [Betagen brand of Betamethasone and Gentamicin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rub-and-spray method (group G, n=10)
Study: 9786313
Drug: irinotecan 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 300 to 350 mg/m2 every 3 weeks
Study: 28060148
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ziv-aflibercept (0.08 mL) intravitreal injection
Study: 26335105
Drug: Completion axillary
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion axillary treatment (completion axillary lymph node dissection or axillary radiation therapy)
Study: 26335105
Drug: No completion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No completion axillary treatment
Study: 21156974
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg (2 capsules) in recovery room, followed by celecoxib 200 mg (1 capsule) twice a day + placebo at bedtime for 3 days after surgery.
Study: 21156974
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg (1 tablet) in recovery room, followed by 400 mg orally 3 times a day for 3 days after surgery.
Study: 18987057
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion (LDI)
Study: 10488711
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake > or =30 g/d
Study: 8729094
Drug: Diet rich
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet rich in n-6 linoleic acid or n-3 alpha-linolenic acid with or without fish oil supplements (n-3 derivatives)
Study: 1908190
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and transcutaneous stimulation analgesia supplemented by small doses of fentanyl (mean 1.2 micrograms/kg, SD 1.7)
Study: 1908190
Drug: Moderate-dose fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose fentanyl anaesthesia (mean 22.9 micrograms/kg, SD 2.8)
Study: 6580492
Drug: Acetylcysteine (N‐acetyl‐L‐cysteine)
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine (N‐acetyl‐L‐cysteine) 1 hour before doxorubicin administration
Study: 29967037
Drug: Self-management (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management (daily home BP monitoring and automated medication reduction via telemonitoring)
Study: 16228107
Drug: Azathioprine (AZ)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZ) 2.5 mg/kg daily for 12 months, then 2 mg/kg daily
Study: 10757579
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% with clonidine 2 microg/kg (1 ml/kg)
Study: 3930128
Drug: 1.0 unit/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 unit/h aVP infusion
Study: 29493395
Drug: Topical azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical azithromycin 15 mg/g ophthalmic solution, used twice a day for 3 days and then once a day until treatment completion (1 month).
Study: 29493395
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 250 mg tablets, 1×2 tablets (500 mg) on the first day, then 1×1 tablet (250 mg) for 4 days, with 3 cycles of treatment and 5-day intervals.
Study: 24671897
Drug: Daily monitored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily monitored device-based parameters (heart rate, thoracic impedance, HR variability, physical activity)
Study: 20182456
Drug: Valsartan/Hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Hydrochlorothiazide combination (320/25 mg)
Study: 15704683
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate supplement in Group I (n = 25)
Study: 11809596
Drug: Benzoyl peroxide/erythromycin
Normalized name: BENZOYL PEROXIDE/ERYTHROMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/erythromycin combination (BP/E)
Study: 10366088
Drug: Placebo DDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DDS (no active drug)
Study: 10366088
Drug: DEX DDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX DDS (1 or 2 doses)
Study: 7746691
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (n = 21), administered twice daily for 2 days
Study: 7746691
Drug: Placebo (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n = 19), administered twice daily for 2 days
Study: 30615169
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral PrEP
Study: 23920048
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of GnRH antagonist daily for 7 days
Study: 23920048
Drug: Standard flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard flexible GnRH antagonist protocol
Study: 19210631
Drug: Ghrelin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (40 microg) administered i.v. over 30 min
Study: 19210631
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) administered i.v. over 30 min
Study: 12768356
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 200 mg levodopa (LD)
Study: 12768356
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 4 mg apomorphine (A)
Study: 3950252
Drug: Cat allergen
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat allergen treatment (15 with cat allergen)
Study: 3950252
Drug: Dog allergen
Normalized name: Recombinant dog allergen 1 specific immunoglobulin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog allergen treatment (7 with dog allergen)
Study: 30920245
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for seasonal affective disorder (CBT-SAD)
Study: 15354376
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy
Study: 9432453
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (control)
Study: 22647089
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (6 mg · kg⁻¹ body-mass)
Study: 20096897
Drug: Soy food-containing
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy food-containing diet with 10 g/d prebiotic (oligofructose-enriched inulin)
Study: 20096897
Drug: Prebiotic (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (10 g/d)
Study: 20096897
Drug: Soy food-containing
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy food-containing diet (30 g/d soy protein, 61 mg/d isoflavones) with 10 g/d placebo (maltodextrin)
Study: 18029465
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/d) plus exercise training (endurance and resistance)
Study: 15910512
Drug: AR-R15896AR 120
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-R15896AR 120 mg
Study: 12095664
Drug: Atomoxetine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 90 mg
Study: 12095664
Drug: Methylphenidate 20
Normalized name: METHYLPHENIDATE 20MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 20 mg and 40 mg
Study: 12095664
Drug: Atomoxetine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 20 mg, 45 mg, and 90 mg
Study: 9875081
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol treatment
Study: 31384899
Drug: SLA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLA and DAE surface treatment methods